YS Biopharma Co. Ltd. (YS)
NASDAQ: YS
· Real-Time Price · USD
1.02
0.09 (9.68%)
At close: May 24, 2024, 10:00 PM
YS Biopharma Balance Sheet Statement
Financials in CNY. Fiscal
year is
undefined.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Cash & Equivalents | 222.61M | 259.91M | 94.75M | 370.11M | 226.77M | -271.07M | 271.07M |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | 542.14M | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 42.05M | 28.03M | 27.07M | 20.92M | 22.66M | -271.07M | 28.23M |
Receivables | 403.12M | 429.37M | 495.91M | 463.05M | 472.81M | n/a | 308.56M |
Inventory | 190.75M | 212.82M | 182.37M | 185.38M | 161.67M | n/a | 166.51M |
Other Current Assets | 10.13M | 11.34M | 6.17M | 10.41M | 561.88K | n/a | 7.99M |
Total Current Assets | 826.61M | 934.61M | 1.01B | 1.04B | 871.55M | 271.07M | 764.76M |
Property-Plant & Equipment | 568.83M | 571.29M | 577.81M | 582.89M | 570.43M | n/a | 565M |
Goodwill & Intangibles | 72.94M | 74.64M | 76.33M | 78.06M | 81.31M | n/a | 80.72M |
Total Long-Term Assets | 683.82M | 676.68M | 683.7M | 683.77M | 676.89M | -271.07M | 676.99M |
Total Assets | 1.51B | 1.61B | 1.69B | 1.72B | 1.55B | n/a | 1.44B |
Account Payables | 77.54M | 84.98M | 73.87M | 80.44M | 37.39M | n/a | 30.81M |
Deferred Revenue | n/a | 2.3M | 2.3M | 2.3M | 3.5M | n/a | 2.3M |
Short-Term Debt | 423.88M | 187.77M | 176.64M | 198.49M | 167.17M | n/a | 116.06M |
Other Current Liabilities | 381.43M | 388.07M | 398.93M | 377.54M | 367.28M | n/a | 326.75M |
Total Current Liabilities | 882.85M | 663.12M | 651.74M | 658.76M | 575.34M | n/a | 475.91M |
Long-Term Debt | 129.11M | 366.43M | 349.97M | 300.14M | 294.4M | n/a | 264.53M |
Other Long-Term Liabilities | 23.96M | 2.19M | 2.38M | 8.79M | 1.61B | n/a | 1.37B |
Total Long-Term Liabilities | 153.07M | 391.07M | 377.39M | 332.54M | 1.92B | n/a | 1.66B |
Total Liabilities | 1.04B | 1.05B | 1.03B | 991.3M | 2.5B | n/a | 2.14B |
Total Debt | 552.99M | 554.2M | 526.61M | 498.63M | 461.56M | n/a | 380.59M |
Common Stock | 12K | 12.3K | 12K | 12.3K | 7.98K | n/a | 7.98K |
Retained Earnings | -2.13B | -2.05B | -1.94B | -1.87B | -1.67B | n/a | -1.59B |
Comprehensive Income | -56.06M | -51.25M | -52.57M | -54.41M | -85.57M | -698.97M | 83.09M |
Shareholders Equity | 474.51M | 557.1M | 660.75M | 728.45M | -950.69M | 671.25M | -698.97M |
Total Investments | n/a | n/a | n/a | n/a | n/a | 542.14M | n/a |